Table 2.
Results of the meta-analysis.
|
Variants vaccines |
Overall Variants |
B.1.1.7 (Alpha) variant |
B.1.351 (Beta) variant |
P.1 (Gamma) variant |
B.1.617.2 (Delta) variant |
B.1.427 (Epsilon) variant |
P.2 (Zeta) variant |
B.1.526 (Iota) variant |
|---|---|---|---|---|---|---|---|---|
| Overall vaccines | 0.07 [0.01; 0.15]* | 0.07 [0.05; 0.10]* | 0.35 [0.04; 0.66]* | 0.14 [0.02; 0.34]* | 0.14 [0.11; 0.18]* | 0.00 [0.00; 0.04]* | NA | NA |
| 0.03 [0.02; 0.04]† | 0.04 [0.03; 0.05]† | 0.09 [0.03; 0.19]† | 0.09 [0.06; 0.16]† | 0.08 [0.05; 0.11]† | 0.00 [0.00; 0.01]† | 0.00 [0.00; 0.22]† | 0.01 [0.00; 0.80]† | |
| 0.40 [0.38, 0.42]§ | 0.66 [0.36; 0.82]§ | 0.16 [0.11; 0.20]§ | 0.35 [0.05; 0.56]§ | 0.38 [0.15; 0.55]§ | 0.78 [0.54; 0.90]§ | NA | NA | |
| 0.96 [0.93; 0.98]¶ | 0.90 [0.79; 0.95]¶ | 0.42 [0.00; 0.70]¶ | 0.61 [0.50; 0.70]¶ | 0.68 [0.57; 0.76]¶ | 0.95 [0.87; 0.98]¶ | 0.69 [0.55; 0.78]¶ | 0.71 [0.00; 0.96]¶ | |
| mRNA vaccine (BNT162b2/mRNA-1273/JNJ-78436735) | 0.07 [0.00; 0.21]* | 0.16 [0.15; 0.16]* | 0.30 [0.14; 0.50]* | 0.09 [0.00; 0.26]* | 0.09 [0.03; 0.18]* | 0.00 [0.00; 0.04]* | NA | NA |
| 0.06 [0.04; 0.09]† | 0.09 [0.06; 0.14]† | 0.10 [0.03; 0.22]† | 0.06 [0.01; 0.16]† | 0.09 [0.05; 0.14]† | 0.00 [0.00; 0.04]† | NA | 0.12 [0.01; 0.59]† | |
| 0.35 [0.13; 0.51]§ | 0.64 [0.00; 0.87]§ | 0.16 [0.11; 0.20]§ | 0.57 [0.05; 0.81]§ | NA | 0.78 [0.54; 0.90]§ | NA | NA | |
| 0.85 [0.28; 0.97]¶ | 0.89 [0.74; 0.95]¶ | 0.40 [0.00; 0.72]¶ | 0.68 [0.00; 0.95]¶ | 0.74 [0.62; 0.82]¶ | 0.95 [0.86; 0.98]¶ | NA | 0.62 [0.00; 0.98]¶ | |
| Viral vector vaccine (ChAdOx1/ChAdOx1-S) | NA | 0.10 [0.07; 0.14]* | NA | NA | 0.06 [0.02; 0.14]* | NA | NA | NA |
| 0.02 [0.01; 0.02]† | 0.00 [0.00; 0.01]† | 0.02 [0.02; 0.03]† | 0.05 [0.00; 0.67]† | 0.03 [0.00; 0.09]† | NA | NA | NA | |
| NA | NA | NA | NA | 0.50 [0.35; 0.61]§ | NA | NA | NA | |
| 0.66 [0.51; 0.77]¶ | 0.94 [0.30; 1.00]¶ | NA | 0.57 [0.25; 0.75]¶ | 0.62 [0.31; 0.79]¶ | NA | NA | NA | |
| Protein subunit vaccine (NVX-CoV2373) | NA | NA | NA | NA | NA | NA | NA | NA |
| 0.03 [0.00; 0.03]† | 0.00 [0.00; 0.00]† | 0.00 [0.00; 0.02]† | NA | NA | NA | NA | NA | |
| NA | NA | NA | NA | NA | NA | NA | NA | |
| NA | 0.89 [0.80; 0.94]¶ | NA | NA | NA | NA | NA | NA | |
| Inactivated vaccine (CoronaVac/BBV152) | NA | NA | NA | NA | NA | NA | NA | NA |
| 0.37 [0.19; 0.57]† | NA | NA | 0.36 [0.26; 0.46]† | NA | NA | NA | NA | |
| NA | NA | NA | NA | NA | NA | NA | NA | |
| NA | NA | NA | NA | NA | NA | NA | NA |
*
Incidence of variants post first vaccine (95% CI).
†
Incidence of variants post second vaccine (95% CI).
§
Vaccine effectiveness post first vaccine (95% CI).
¶
Vaccine effectiveness post second vaccine (95% CI).
NA, not applicable; CI, confidence interval.